Literature DB >> 8287063

Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males.

N Rothman1, R B Hayes, W Bi, N Caporaso, F Broly, R L Woosley, S Yin, P Feng, X You, U A Meyer.   

Abstract

Eighty-four healthy Chinese male control subjects derived from an occupation-based case-control study of bladder cancer were evaluated for hepatic N-acetyltransferase activity by dapsone and for NAT2 genotype using allele-specific amplification of peripheral leukocyte DNA by the polymerase chain reaction. Fifty-nine percent of the overall variation in acetylation activity was explained by genotype (p < 0.0001). The remaining variation in acetylation was not associated with dapsone N-hydroxylation activity, age, current smoking status, or weight in the study population, or within any genotype subgroup. Although acetylation activity in the homozygous mutant group did not overlap with the other genotype categories, there was moderate overlap in acetylation between the heterozygous mutant and wildtype groups, and substantial variation in acetylation within them. Considering all subjects with the identical NAT2 genotype as phenotypically similar and all subjects with differing NAT2 genotypes as phenotypically distinct may result in misclassification of metabolic risk factors in epidemiological investigations. As such, it would seem prudent, where possible, to collect both acetylation phenotype and NAT2 genotype data, since the advantages and limitations of these two sources of information complement, and serve to assess the accuracy of each other.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8287063     DOI: 10.1097/00008571-199310000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  10 in total

1.  A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid.

Authors:  C A Smith; M Wadelius; A C Gough; D J Harrison; C R Wolf; A Rane
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

2.  Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.

Authors:  I Cascorbi; N Drakoulis; J Brockmöller; A Maurer; K Sperling; I Roots
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

Review 3.  Pharmacogenetic phenotyping and genotyping. Present status and future potential.

Authors:  F J Gonzalez; J R Idle
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

4.  The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population.

Authors:  Bing Chen; Wei-Xia Zhang; Wei-Min Cai
Journal:  Eur J Clin Pharmacol       Date:  2006-03-29       Impact factor: 2.953

5.  Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity.

Authors:  Mahmoud Abouraya; James C Sacco; Kristie Hayes; Sajeve Thomas; Craig S Kitchens; Lauren A Trepanier
Journal:  J Clin Pharmacol       Date:  2012-02       Impact factor: 3.126

6.  Genetic heterogeneity among slow acetylator N-acetyltransferase 2 phenotypes in cryopreserved human hepatocytes.

Authors:  Mark A Doll; David W Hein
Journal:  Arch Toxicol       Date:  2017-05-17       Impact factor: 5.153

7.  The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers.

Authors:  N Rothman; V K Bhatnagar; R B Hayes; T V Zenser; S K Kashyap; M A Butler; D A Bell; V Lakshmi; M Jaeger; R Kashyap; A Hirvonen; P A Schulte; M Dosemeci; F Hsu; D J Parikh; B B Davis; G Talaska
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

8.  Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.

Authors:  Valery V Bakayev; Forozan Mohammadi; Moslem Bahadori; Mariam Sheikholslami; Arash Javeri; Mohammad R Masjedi; Ali A Velayati
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

9.  Effects of dietary factors and the NAT2 acetylator status on gastric cancer in Koreans.

Authors:  Yan Wei Zhang; Sang-Yong Eom; Yong-Dae Kim; Young-Jin Song; Hyo-Yung Yun; Joo-Seung Park; Sei-Jin Youn; Byung Sik Kim; Heon Kim; David W Hein
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

Review 10.  Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.

Authors:  A Hirvonen
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.